Determination of Regulatory Review Period for Purposes of Patent Extension; BRIDION

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for BRIDION, a human drug product, and is publishing this notice as required by law. FDA made this determination due to a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO), Department of Commerce.